MYRIAD GENETICS INC
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
MYGN$5.67-1.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows for the Years Ended
Consolidated Statements of Cash Flows
| Years Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | |||
| Net loss | $(365.9) | $(127.3) | $(263.3) |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | |||
| Depreciation and amortization | 53.7 | 61.2 | 61.9 |
| Non-cash lease expense | 7.7 | 9.5 | 11.3 |
| Stock-based compensation expense | 35.2 | 49.8 | 40.7 |
| Deferred income taxes | 0.1 | (2.8) | (4.0) |
| Unrecognized tax benefits | (32.5) | 2.5 | 3.4 |
| Impairment of goodwill and long-lived assets | 319.4 | 56.6 | — |
| (Gain) loss on termination of lease | — | (3.1) | 7.7 |
| Gain on acquisition | — | (2.2) | — |
| Other non-cash adjustments | 3.4 | 1.5 | 4.4 |
| Changes in assets and liabilities: | |||
| Prepaid expenses and other current assets | 0.2 | (3.7) | 0.2 |
| Trade accounts receivable | 6.2 | (8.7) | (12.5) |
| Inventory | (3.2) | (6.2) | (1.8) |
| Prepaid taxes | 4.4 | 0.5 | 0.7 |
| Other assets | 2.0 | — | 0.6 |
| Tenant improvement allowance received | — | — | 16.3 |
| Accounts payable | (1.4) | 4.7 | (3.7) |
| Accrued liabilities | (27.5) | (41.0) | 27.2 |
| Net cash provided by (used in) operating activities | 1.8 | (8.7) | (110.9) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | |||
| Capital expenditures | (15.6) | (19.0) | (63.2) |
| Capitalization of intangible assets | (11.8) | (10.7) | (10.1) |
| Proceeds from the sale of business, net cash sold | — | 8.8 | — |
| Proceeds from maturities and sales of marketable investment securities | — | 9.0 | 105.2 |
| Net cash (used in) provided by investing activities | (27.4) | (11.9) | 31.9 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | |||
| Proceeds from common stock issued under stock-based compensation plans | 3.3 | 5.9 | 6.0 |
| Payment of tax withheld for common stock issued under stock-based compensation plans | (7.3) | (13.4) | (8.8) |
| Proceeds from underwritten public offering, net of costs and discounts | — | — | 117.6 |
| Proceeds from revolving credit facility | 40.0 | 120.0 | 80.0 |
| Repayment of revolving credit facility | (80.5) | (119.5) | (40.0) |
| Proceeds from the issuance of secured long-term credit facility | 125.0 | — | — |
| Fees associated with the issuance of secured long-term credit facility | (8.6) | — | — |
| Fees associated with issuance and refinancing of revolving credit facility | — | — | (1.7) |
| Release of cash held in escrow | (7.5) | — | — |
| Other financing activities | (0.2) | (0.4) | (0.2) |
| Net cash provided by (used in) financing activities | 64.2 | (7.4) | 152.9 |
| Effect of foreign exchange rates on cash, cash equivalents, and restricted cash | 0.8 | (1.0) | 0.6 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 39.4 | (29.0) | 74.5 |
| Cash, cash equivalents, and restricted cash at beginning of the period | 111.9 | 140.9 | 66.4 |
| Cash, cash equivalents, and restricted cash at end of the period | $151.3 | $111.9 | $140.9 |
See accompanying notes to the consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.